-
Mashup Score: 4JNCCN - 27 day(s) ago
JNCCN
Source: jnccn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity - 1 month(s) ago
Background: Although the need to reduce the impact of financial toxicity among patients with cancer is widely acknowledged, few interventions have been developed to address this issue. We tested a novel, multiphase, patient-centered financial navigation (FN) intervention at a large academic medical center. Methods: We developed a financial toxicity screening tool consisting of the Comprehensive Score for Financial Toxicity (COST) measure plus several additional items based on patient feedback. After systematizing the screening process, 50 patients from the North Carolina Basnight Cancer Hospital were enrolled in the FN intervention following a positive screen for financial distress (COST score <23). The FN intervention involved one-on-one consultations with a trained financial navigator and included an initial comprehensive intake appointment to determine patient eligibility for financial assistance and follow-up appointments to discuss paperwork and application(s) status. We assessed
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related #FinancialToxicity: https://t.co/VsCdvkErvA https://t.co/7jidY44EH9
-
-
Mashup Score: 39The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis - 2 month(s) ago
Background: HPV infection is implicated in approximately half of global penile squamous cell carcinoma (PSCC) cases. Previous studies on HPV DNA and p16INK4a status in PSCC have yielded inconclusive prognostic findings. This meta-analysis aims to elucidate the prognostic role of HPV in PSCC by pooling data on disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). Methods: We systematically searched Medline and Embase up to January 2023 for relevant human studies. Data from eligible publications reporting HPV DNA or p16INK4a status, along with and DFS, DSS, or OS outcomes, were extracted. A random-effects meta-analysis model was used to synthesize data, with study weights based on size and significance. The study protocol was registered with PROSPERO (CRD42019131355). Results: Out of 544 studies screened, 34 publications were included, comprising a pooled sample size of 3,944 patients. p16INK4a-positive status was associated with improved OS (hazard rat
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
‼️🚨The best current evidence on the role of HPV in Penile Cancer: A Meta-Analysis by our group @MoffittNews @SpiessPhilippe @AnnaGiuliano19 @CurtisPettaway1 @MajdAssaad @HPVRoundtable @hsafaMD @StopHPVCancer @HPVAction @MaHPVCoalition @FightHPVcancer https://t.co/V9sIWXVKlw
-
-
Mashup Score: 3The Oncologist Outside the Exam Room - 2 month(s) ago
“The Oncologist Outside the Exam Room” published on Dec 2024 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
Thank you @JNCCN for a fun interview and for allowing me to share my thoughts on the critical role oncologists play outside the exam room. Yes; I had to mention my books and I do share my thoughts where AI affects cancer care today & in the future, https://t.co/vTigexX93W
-
-
Mashup Score: 27Oncology Survivorship Care Clinics: Design and Implementation of Survivorship Care Delivery Systems at NCCN Member Institutions - 3 month(s) ago
Background: It is estimated that there are >18 million cancer survivors in the United States, and there is a growing number of survivorship programs across the country to care for these individuals. There is a clear need for survivorship care; however, evidence is still emerging on how to best operationalize the guidance from nationally recognized organizations and clinical practice guidelines. Methods: The NCCN Best Practices Committee (BPC) recently conducted a survey to better understand survivorship clinics at NCCN Member Institutions. Representatives from 24 of the 33 NCCN Member Institutions (73%) submitted responses to the survey. Results: Although all responding centers see cancer survivors, most (92%) have ≥1 dedicated survivorship clinics. Of those centers with dedicated survivorship clinics (n=22), 9 (41%) reported general survivorship clinics for all cancer types, and 13 (59%) indicated their center offered ≥1 disease-specific survivorship clinics. Most centers (55%) use a
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet-
Survivorship means different things to different individuals. Oncology Survivorship Care Clinics: Design & Implementation of Survivorship Care Delivery Systems at NCCN Member Institutions @JNCCN @OncoAlert @CancerAdvocacy https://t.co/0EcY1vyCqI
-
-
Mashup Score: 4JNCCN - 3 month(s) ago
JNCCN
Source: jnccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
The August issue of @JNCCN is now available online! Featured: @NCCN Guidelines on Adolescent and Young Adult (#AYA) Oncology, insights into recent updates to #NCCNGuidelines for #Survivorship, and more! https://t.co/8t8aPaSww2 #AYAcsm #survonc https://t.co/WiN2kzpsqA
-
-
Mashup Score: 5Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer - 3 month(s) ago
Background: Hormone receptor (HR)–negative, HER2-positive (also called HER2-enriched) breast cancer has no worse prognosis than other breast cancers if it is treated with HER2-targeted therapy. Medicaid expansion under the Affordable Care Act (ACA) has been shown to be associated with improved access to care and outcomes for many cancers, but its association with receipt of care for HR-negative, HER2-positive breast cancer is unknown. We examined the association of Medicaid expansion with receipt of guideline-concordant treatment, time to treatment initiation, and survival among nonelderly women newly diagnosed with HR-negative, HER2-positive breast cancer. Patients and Methods: Women aged 18 to 62 years newly diagnosed with HR-negative, HER2-positive breast cancer between 2010 and 2018 were identified from the National Cancer Database. Outcomes included receipt of stage-based guideline-concordant treatment, timely initiation of treatment (<30 days, <60 days, <90 days from diagnosis),
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Association of #Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive #BreastCancer: https://t.co/khSFcYl4Dv @KSylvia_Shi @DrRobinYabroff @XuJi2022 @CharlesJiangMD @KathrynRuddyMD @SharonCastelli2 @HanXuesong #BCSM https://t.co/xhJnlFU7TU
-
-
Mashup Score: 0Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA) - 3 month(s) ago
Peripheral and deep en face margin assessment (PDEMA), formerly termed by NCCN as complete circumferential peripheral and deep margin assessment (CCPDMA), has the advantages of histologic visualization of the entire marginal surface, highly accurate resection of involved tissue, and sparing of uninvolved tissue. Owing to its highest reported cure rates, PDEMA is the NCCN-preferred treatment for dermatofibrosarcoma protuberans, high-risk basal cell carcinoma, and very-high-risk cutaneous squamous cell carcinoma. In the United States, Mohs micrographic surgery (Mohs) is the most common method of PDEMA. In Germany and some other countries, non-Mohs methods of PDEMA referred to as the Tubingen torte and muffin techniques are more widely used. The Tubingen methods of PDEMA require close communication between surgeon and pathologist. This article describes the background of both Mohs and Tubingen PDEMA, reviews what constitutes PDEMA, and provides a protocol for Tubingen PDEMA detailing crit
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Achieving Adherence With #NCCNGuidelines for Nonmelanoma #SkinCancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA): https://t.co/GvmpvzoPqJ #skcsm https://t.co/cRnI0PuLdK
-
-
Mashup Score: 4Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity - 4 month(s) ago
Background: Although the need to reduce the impact of financial toxicity among patients with cancer is widely acknowledged, few interventions have been developed to address this issue. We tested a novel, multiphase, patient-centered financial navigation (FN) intervention at a large academic medical center. Methods: We developed a financial toxicity screening tool consisting of the Comprehensive Score for Financial Toxicity (COST) measure plus several additional items based on patient feedback. After systematizing the screening process, 50 patients from the North Carolina Basnight Cancer Hospital were enrolled in the FN intervention following a positive screen for financial distress (COST score <23). The FN intervention involved one-on-one consultations with a trained financial navigator and included an initial comprehensive intake appointment to determine patient eligibility for financial assistance and follow-up appointments to discuss paperwork and application(s) status. We assessed
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related #FinancialToxicity: https://t.co/VsCdvkErvA https://t.co/7jidY44EH9
-
-
Mashup Score: 5Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma - 4 month(s) ago
Older patients with multiple myeloma (MM) exhibit wide heterogeneity in their baseline physiologic and functional status, which demands an individualized treatment approach based on biological rather than chronological age. Various frailty scores have been developed for older patients with MM, but they are underutilized in clinical trials and in practice. Older patients with MM are underrepresented in therapeutic clinical trials, and treatment recommendations are currently derived from clinical trials of transplant-ineligible patients. This article provides a summary of phase II and III clinical trials in transplant-ineligible patients with newly diagnosed MM, highlighting outcomes in patients aged ≥75 years and frailty-based outcomes. The data available thus far show that triplet regimens are more efficacious than doublets in older patients but may be associated with higher toxicity. DRd (daratumumab/lenalidomide/dexamethasone) and VRd (bortezomib/lenalidomide/dexamethasone) are good
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With #MultipleMyeloma: https://t.co/60ohiHFooA #MMSM #gerinonc #hemeonc @siennadurbin @ryannipp @lundquistdebra https://t.co/UELVHB9g63
-
The August issue of @JNCCN is now available online! Featured: @NCCN Guidelines on Adolescent and Young Adult (#AYA) Oncology, insights into recent updates to #NCCNGuidelines for #Survivorship, and more! https://t.co/8t8aPaSww2 #AYAcsm #survonc https://t.co/WiN2kzpsqA